We presented the following oral presentations at ECTRIMS 2025
Roos et al: Real world effectiveness of ocrelizumab in multiple sclerosis: a multi-registry observational cohort study
Lizak et al: Confirmed disability improvement as a longterm prognostic marker in MS
We presented the following posters at ECTRIMS 2025
Abad-Inchaurrondo et al: Performance of the 2024 McDonald diagnostic criteria for MS
Burford-Baynes et al: Disease milestones in MS: The impact of active and inactive PIRA and RAW
Haile et al: Causal effects of MS therapies in left-truncated registry data
Hogenboom et al: Predictors of B-cell repopulation in ocrelizumab treated patients: Insights from two large cohorts
Iqbal et al: Machine learning-generated stimulated MS cohort
Kalincik et al: Effectiveness of autologous haematopoietic stem cell transplant in comparison with anti-CD20 therapies in relapsing-remitting MS
Müller et al: Treatment strategies after cell-trafficking agents in MS patients older than 50 years
Qiang et al: Synthetic international MS cohort (SIMS) – Longitudinal
Roberts et al: A data-driven approach to triaging multiple sclerosis patients presenting with cognitive complaints
Roos et al: Cladribine as an exit strategy in people with MS over the age of 50